Medentseva O. Optimization of treatment and prognosis in patients with ischemic heart failure with concomitant type 2 diabetes mellitus based on the study of the marker of ST2 fibrosis and the M235T polymorphism of the angiotensinogen gene.

The dissertation is devoted to the actual problem of modern medicine - to increase the effectiveness of treatment with renin-angiotensin-aldosterone system blockers and to improve prediction of heart failure with a preserved left ventricular ejection fraction (HFpEF) in patients with type 2 diabetes mellitus (DM).The association of the T allele of the M235T polymorphism with the development of lipid metabolism disorders, a marker of ST2 myocardial fibrosis in patients with HFpEF on the background of type 2 diabetes has been established. The data on the prognostic role of the ST2 biomarker and the M235T polymorphism of the ATG gene in the comorbidity of HFpEF and type 2 DM were obtained. By constructing a model for predicting the risk of adverse events, the genotypes of TT and MT of the M235T polymorphism of the ATG gene and elevated ST2 level were determined as independent predictors of the development of adverse events in patients with HFpEF and type 2 DM. The efficacy of differentiated use of RAAS blockers in patients with type 2 diabetes and diabetes is substantiated.